LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

Home・Akciju saraksts・Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals Inc

Slēgts

SektorsVeselības aprūpe

61.58 -2.79

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

60.79

Max

64.37

Galvenie mērījumi
By Trading Economics
Ienākumi	52M 28M
Pārdošana	7.6M 264M
P/E Sektora vidējais	39.463 108.767
EPS	0.22
Peļņas marža	10.696
Darbinieki	711
EBITDA	206M 57M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+28.79% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 11. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-1.4B 8.8B
Iepriekšējā atvēršanas cena	64.37
Iepriekšējā slēgšanas cena	61.58

Ziņu noskaņojums

By Acuity

50%

167 / 351 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bearish Evidence

11.5 / 12.23 Atbalsts un pretestība

Arrowhead Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 25. febr. 23:25 UTC

Karstas akcijas

Stocks to Watch: C3.ai, Salesforce, Pure Storage, Zoom

2026. g. 25. febr. 23:15 UTC

Peļņas

Salesforce Sees Stable Growth; CEO Dismisses Talk of AI-Fueled 'SaaS-Pocalypse' -- 2nd Update

2026. g. 25. febr. 23:54 UTC

Tirgus saruna

Gold Steady Ahead of U.S.-Iran Talks -- Market Talk

2026. g. 25. febr. 23:47 UTC

Peļņas

Ferrovial 4Q Net EUR197M >FER.MC

2026. g. 25. febr. 23:45 UTC

Peļņas

Ferrovial 4Q Rev EUR2.72B >FER.MC

2026. g. 25. febr. 23:42 UTC

Peļņas

Nvidia Beats Back Bubble Fears With Record $68 Billion Sales in Fourth Quarter -- 4th Update

2026. g. 25. febr. 23:38 UTC

Tirgus saruna

Nikkei May Rise, Tracking Wall Street's Gains -- Market Talk

2026. g. 25. febr. 23:25 UTC

Peļņas

Trip.com: Company's Business Operations Remain Normal >TCOM

2026. g. 25. febr. 23:25 UTC

Peļņas

Trip.com Gives Update on Investigation by China's State Administration for Market Regulation >TCOM

2026. g. 25. febr. 23:25 UTC

Peļņas

Trip.com: Cannot Predict Status or Results of Investigation, Will Provide Updates on Conclusion >TCOM

2026. g. 25. febr. 23:25 UTC

Peļņas

Trip.com Increase in FY Profit Primarily Due to Gain From Investments >TCOM

2026. g. 25. febr. 23:25 UTC

Peļņas

Trip.com Will Continue to Communicate With SAMR on Compliance With Regulatory Requirements >TCOM

2026. g. 25. febr. 23:25 UTC

Peļņas

Trip.com: SAMR Investigation Related to China's Anti-monopoly Law >TCOM

2026. g. 25. febr. 23:25 UTC

Peļņas

Trip.com: Investigation Ongoing, Company Is Cooperating With SAMR >TCOM

2026. g. 25. febr. 23:25 UTC

Peļņas

Trip.com Co-founders Min Fan, Qi Ji Resign From Positions >TCOM

2026. g. 25. febr. 23:25 UTC

Peļņas

Trip.com: Fan Resigned as Director and President; Ji Resigned as a Director >TCOM

2026. g. 25. febr. 23:25 UTC

Peļņas

Trip.com FY Rev CNY62.4B, Up 17% >TCOM

2026. g. 25. febr. 23:25 UTC

Peļņas

Trip.com FY Net CNY33.3B Vs. Net CNY17.1B >TCOM

2026. g. 25. febr. 23:25 UTC

Peļņas

Trip.com FY EPS CNY47.67 >TCOM

2026. g. 25. febr. 23:06 UTC

Peļņas

Correction to Nvidia Fourth Quarter Results Article -- WSJ

2026. g. 25. febr. 23:01 UTC

Peļņas

Nvidia Beats Back Bubble Fears With Record $68 Billion Sales in Fourth Quarter -- 3rd Update

2026. g. 25. febr. 23:00 UTC

Tirgus saruna

Peļņas

Global Equities Roundup: Market Talk

2026. g. 25. febr. 23:00 UTC

Tirgus saruna

Peļņas

Nvidia: Chinese Competitors Pose Risk to U.S. Dominance in AI -- Market Talk

2026. g. 25. febr. 22:56 UTC

Tirgus saruna

Peļņas

Nvidia CEO Says Customers Can't Grow Revenue Without Compute -- Market Talk

2026. g. 25. febr. 22:43 UTC

Peļņas

Iegādes, apvienošanās, pārņemšana

Paramount Streaming Revenue Rises, but TV Segment Faces Headwinds -- WSJ

2026. g. 25. febr. 22:40 UTC

Tirgus saruna

Peļņas

Nvidia Says Agentic AI Has Reached Inflection Point -- Market Talk

2026. g. 25. febr. 22:40 UTC

Peļņas

Karoon Energy Says Search for New CFO Well Advanced

2026. g. 25. febr. 22:39 UTC

Peļņas

Karoon Energy Says CFO Ray Church to Leave Company

2026. g. 25. febr. 22:39 UTC

Peļņas

Karoon Energy Says On-Market Share Buyback Program Ongoing at Moderated Level

2026. g. 25. febr. 22:38 UTC

Peļņas

Karoon Energy Says Guidance for 2026 Key Metrics Unchanged

Salīdzinājums

Cenas izmaiņa

Arrowhead Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

28.79% augšup

Prognoze 12 mēnešiem

Vidējais 82 USD 28.79%

Augstākais 110 USD

Zemākais 35 USD

Pamatojoties uz 11 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Arrowhead Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

11 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 11 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Arrowhead Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

11.5 / 12.23Atbalsts un pretestība

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

There is one bearish event.

Noskaņojums

By Acuity

167 / 351 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.